Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-Current Deffered Revenue: 2010-2014

Historic Non-Current Deffered Revenue for Vanda Pharmaceuticals (VNDA) over the last 5 years, with Dec 2014 value amounting to $3.1 million.

  • Vanda Pharmaceuticals' Non-Current Deffered Revenue fell 95.12% to $3.1 million in Q4 2014 from the same period last year, while for Dec 2014 it was $3.1 million, marking a year-over-year decrease of 95.12%. This contributed to the annual value of $3.1 million for FY2014, which is 95.12% down from last year.
  • According to the latest figures from FY2014, Vanda Pharmaceuticals' Non-Current Deffered Revenue is $3.1 million, which was down 95.12% from $63.5 million recorded in FY2013.
  • Vanda Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $143.9 million during FY2010, with a 5-year trough of $3.1 million in FY2014.
  • Over the past 3 years, Vanda Pharmaceuticals' median Non-Current Deffered Revenue value was $63.5 million (recorded in 2013), while the average stood at $52.3 million.
  • Data for Vanda Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY plummeted of 95.12% (in 2014) over the last 5 years.
  • Vanda Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $143.9 million in 2010, then dropped by 18.62% to $117.1 million in 2011, then dropped by 22.88% to $90.3 million in 2012, then fell by 29.67% to $63.5 million in 2013, then plummeted by 95.12% to $3.1 million in 2014.